- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
The Oncology Biosimilars market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Oncology Biosimilars size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Oncology Biosimilars market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Oncology Biosimilars market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Monoclonal Antibody
Hematopoietic Agents
G-CSF
Others
Market segment by Application can be divided into
Retail Pharmacies
Hospital Pharmacy
Online Pharmacy
The key market players for global Oncology Biosimilars market are listed below:
Celltrion
Biocon
Dr. Reddy’s Laboratories
STADA Arzneimittel AG
Intas Pharmaceuticals
Pfizer
Sandoz International
Teva Pharmaceutical Industries Ltd
Apotex
BIOCAD
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Oncology Biosimilars product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Oncology Biosimilars, with price, sales, revenue and global market share of Oncology Biosimilars from 2019 to 2021.
Chapter 3, the Oncology Biosimilars competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Oncology Biosimilars breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Oncology Biosimilars market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Oncology Biosimilars sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Oncology Biosimilars Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Oncology Biosimilars Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Monoclonal Antibody
1.2.3 Hematopoietic Agents
1.2.4 G-CSF
1.2.5 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Oncology Biosimilars Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Retail Pharmacies
1.3.3 Hospital Pharmacy
1.3.4 Online Pharmacy
1.4 Global Oncology Biosimilars Market Size & Forecast
1.4.1 Global Oncology Biosimilars Sales in Value (2016-2026))
1.4.2 Global Oncology Biosimilars Sales in Volume (2016-2026)
1.4.3 Global Oncology Biosimilars Price by Type (2016-2026) & (US$/Unit)
1.5 Global Oncology Biosimilars Production Capacity Analysis
1.5.1 Global Oncology Biosimilars Total Production Capacity (2016-2026)
1.5.2 Global Oncology Biosimilars Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Oncology Biosimilars Market Drivers
1.6.2 Oncology Biosimilars Market Restraints
1.6.3 Oncology Biosimilars Trends Analysis
2 Manufacturers Profiles
2.1 Celltrion
2.1.1 Celltrion Details
2.1.2 Celltrion Major Business
2.1.3 Celltrion Oncology Biosimilars Product and Services
2.1.4 Celltrion Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Biocon
2.2.1 Biocon Details
2.2.2 Biocon Major Business
2.2.3 Biocon Oncology Biosimilars Product and Services
2.2.4 Biocon Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Dr. Reddy’s Laboratories
2.3.1 Dr. Reddy’s Laboratories Details
2.3.2 Dr. Reddy’s Laboratories Major Business
2.3.3 Dr. Reddy’s Laboratories Oncology Biosimilars Product and Services
2.3.4 Dr. Reddy’s Laboratories Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 STADA Arzneimittel AG
2.4.1 STADA Arzneimittel AG Details
2.4.2 STADA Arzneimittel AG Major Business
2.4.3 STADA Arzneimittel AG Oncology Biosimilars Product and Services
2.4.4 STADA Arzneimittel AG Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Intas Pharmaceuticals
2.5.1 Intas Pharmaceuticals Details
2.5.2 Intas Pharmaceuticals Major Business
2.5.3 Intas Pharmaceuticals Oncology Biosimilars Product and Services
2.5.4 Intas Pharmaceuticals Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Pfizer
2.6.1 Pfizer Details
2.6.2 Pfizer Major Business
2.6.3 Pfizer Oncology Biosimilars Product and Services
2.6.4 Pfizer Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Sandoz International
2.7.1 Sandoz International Details
2.7.2 Sandoz International Major Business
2.7.3 Sandoz International Oncology Biosimilars Product and Services
2.7.4 Sandoz International Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Teva Pharmaceutical Industries Ltd
2.8.1 Teva Pharmaceutical Industries Ltd Details
2.8.2 Teva Pharmaceutical Industries Ltd Major Business
2.8.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product and Services
2.8.4 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 Apotex
2.9.1 Apotex Details
2.9.2 Apotex Major Business
2.9.3 Apotex Oncology Biosimilars Product and Services
2.9.4 Apotex Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.10 BIOCAD
2.10.1 BIOCAD Details
2.10.2 BIOCAD Major Business
2.10.3 BIOCAD Oncology Biosimilars Product and Services
2.10.4 BIOCAD Oncology Biosimilars Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Oncology Biosimilars Sales by Manufacturer
3.1 Global Oncology Biosimilars Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Oncology Biosimilars Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Oncology Biosimilars
3.4 Market Concentration Rate
3.4.1 Top 3 Oncology Biosimilars Manufacturer Market Share
3.4.2 Top 6 Oncology Biosimilars Manufacturer Market Share
3.5 Global Oncology Biosimilars Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Oncology Biosimilars Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Oncology Biosimilars Market Size by Region
4.1.1 Global Oncology Biosimilars Sales in Volume by Region (2016-2026)
4.1.2 Global Oncology Biosimilars Revenue by Region (2016-2026)
4.2 North America Oncology Biosimilars Revenue (2016-2026)
4.3 Europe Oncology Biosimilars Revenue (2016-2026)
4.4 Asia-Pacific Oncology Biosimilars Revenue (2016-2026)
4.5 South America Oncology Biosimilars Revenue (2016-2026)
4.6 Middle East and Africa Oncology Biosimilars Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Oncology Biosimilars Sales in Volume by Type (2016-2026)
5.2 Global Oncology Biosimilars Revenue by Type (2016-2026)
5.3 Global Oncology Biosimilars Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Oncology Biosimilars Sales in Volume by Application (2016-2026)
6.2 Global Oncology Biosimilars Revenue by Application (2016-2026)
6.3 Global Oncology Biosimilars Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Oncology Biosimilars Sales by Type (2016-2026)
7.2 North America Oncology Biosimilars Sales by Application (2016-2026)
7.3 North America Oncology Biosimilars Market Size by Country
7.3.1 North America Oncology Biosimilars Sales in Volume by Country (2016-2026)
7.3.2 North America Oncology Biosimilars Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Oncology Biosimilars Sales by Type (2016-2026)
8.2 Europe Oncology Biosimilars Sales by Application (2016-2026)
8.3 Europe Oncology Biosimilars Market Size by Country
8.3.1 Europe Oncology Biosimilars Sales in Volume by Country (2016-2026)
8.3.2 Europe Oncology Biosimilars Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Oncology Biosimilars Sales by Type (2016-2026)
9.2 Asia-Pacific Oncology Biosimilars Sales by Application (2016-2026)
9.3 Asia-Pacific Oncology Biosimilars Market Size by Region
9.3.1 Asia-Pacific Oncology Biosimilars Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Oncology Biosimilars Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Oncology Biosimilars Sales by Type (2016-2026)
10.2 South America Oncology Biosimilars Sales by Application (2016-2026)
10.3 South America Oncology Biosimilars Market Size by Country
10.3.1 South America Oncology Biosimilars Sales in Volume by Country (2016-2026)
10.3.2 South America Oncology Biosimilars Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Oncology Biosimilars Sales by Type (2016-2026)
11.2 Middle East & Africa Oncology Biosimilars Sales by Application (2016-2026)
11.3 Middle East & Africa Oncology Biosimilars Market Size by Country
11.3.1 Middle East & Africa Oncology Biosimilars Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Oncology Biosimilars Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Oncology Biosimilars Typical Distributors
12.3 Oncology Biosimilars Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Oncology Biosimilars Revenue by Type, (USD Million), 2021-2026
Table 2. Global Oncology Biosimilars Revenue by Application, (USD Million), 2021-2026
Table 3. Celltrion Basic Information, Manufacturing Base and Competitors
Table 4. Celltrion Major Business
Table 5. Celltrion Oncology Biosimilars Product and Services
Table 6. Celltrion Oncology Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Biocon Basic Information, Manufacturing Base and Competitors
Table 8. Biocon Major Business
Table 9. Biocon Oncology Biosimilars Product and Services
Table 10. Biocon Oncology Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Dr. Reddy’s Laboratories Basic Information, Manufacturing Base and Competitors
Table 12. Dr. Reddy’s Laboratories Major Business
Table 13. Dr. Reddy’s Laboratories Oncology Biosimilars Product and Services
Table 14. Dr. Reddy’s Laboratories Oncology Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. STADA Arzneimittel AG Basic Information, Manufacturing Base and Competitors
Table 16. STADA Arzneimittel AG Major Business
Table 17. STADA Arzneimittel AG Oncology Biosimilars Product and Services
Table 18. STADA Arzneimittel AG Oncology Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Intas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 20. Intas Pharmaceuticals Major Business
Table 21. Intas Pharmaceuticals Oncology Biosimilars Product and Services
Table 22. Intas Pharmaceuticals Oncology Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Pfizer Basic Information, Manufacturing Base and Competitors
Table 24. Pfizer Major Business
Table 25. Pfizer Oncology Biosimilars Product and Services
Table 26. Pfizer Oncology Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Sandoz International Basic Information, Manufacturing Base and Competitors
Table 28. Sandoz International Major Business
Table 29. Sandoz International Oncology Biosimilars Product and Services
Table 30. Sandoz International Oncology Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Teva Pharmaceutical Industries Ltd Basic Information, Manufacturing Base and Competitors
Table 32. Teva Pharmaceutical Industries Ltd Major Business
Table 33. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product and Services
Table 34. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Apotex Basic Information, Manufacturing Base and Competitors
Table 36. Apotex Major Business
Table 37. Apotex Oncology Biosimilars Product and Services
Table 38. Apotex Oncology Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. BIOCAD Basic Information, Manufacturing Base and Competitors
Table 40. BIOCAD Major Business
Table 41. BIOCAD Oncology Biosimilars Product and Services
Table 42. BIOCAD Oncology Biosimilars Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. Global Oncology Biosimilars Sales by Manufacturer (2019-2021e) & (K Units)
Table 44. Global Oncology Biosimilars Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 45. Market Position of Manufacturers in Oncology Biosimilars, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 46. Global Oncology Biosimilars Production Capacity by Company, (K Units): 2020 VS 2021
Table 47. Head Office and Oncology Biosimilars Production Site of Key Manufacturer
Table 48. Oncology Biosimilars New Entrant and Capacity Expansion Plans
Table 49. Oncology Biosimilars Mergers & Acquisitions in the Past Five Years
Table 50. Global Oncology Biosimilars Sales by Region (2016-2021e) & (K Units)
Table 51. Global Oncology Biosimilars Sales by Region (2021-2026) & (K Units)
Table 52. Global Oncology Biosimilars Revenue by Region (2016-2021e) & (USD Million)
Table 53. Global Oncology Biosimilars Revenue by Region (2021-2026) & (USD Million)
Table 54. Global Oncology Biosimilars Sales by Type (2016-2021e) & (K Units)
Table 55. Global Oncology Biosimilars Sales by Type (2021-2026) & (K Units)
Table 56. Global Oncology Biosimilars Revenue by Type (2016-2021e) & (USD Million)
Table 57. Global Oncology Biosimilars Revenue by Type (2021-2026) & (USD Million)
Table 58. Global Oncology Biosimilars Price by Type (2016-2021e) & (US$/Unit)
Table 59. Global Oncology Biosimilars Price by Type (2021-2026) & (US$/Unit)
Table 60. Global Oncology Biosimilars Sales by Application (2016-2021e) & (K Units)
Table 61. Global Oncology Biosimilars Sales by Application (2021-2026) & (K Units)
Table 62. Global Oncology Biosimilars Revenue by Application (2016-2021e) & (USD Million)
Table 63. Global Oncology Biosimilars Revenue by Application (2021-2026) & (USD Million)
Table 64. Global Oncology Biosimilars Price by Application (2016-2021e) & (US$/Unit)
Table 65. Global Oncology Biosimilars Price by Application (2021-2026) & (US$/Unit)
Table 66. North America Oncology Biosimilars Sales by Country (2016-2021e) & (K Units)
Table 67. North America Oncology Biosimilars Sales by Country (2021-2026) & (K Units)
Table 68. North America Oncology Biosimilars Revenue by Country (2016-2021e) & (USD Million)
Table 69. North America Oncology Biosimilars Revenue by Country (2021-2026) & (USD Million)
Table 70. North America Oncology Biosimilars Sales by Type (2016-2021e) & (K Units)
Table 71. North America Oncology Biosimilars Sales by Type (2021-2026) & (K Units)
Table 72. North America Oncology Biosimilars Sales by Application (2016-2021e) & (K Units)
Table 73. North America Oncology Biosimilars Sales by Application (2021-2026) & (K Units)
Table 74. Europe Oncology Biosimilars Sales by Country (2016-2021e) & (K Units)
Table 75. Europe Oncology Biosimilars Sales by Country (2021-2026) & (K Units)
Table 76. Europe Oncology Biosimilars Revenue by Country (2016-2021e) & (USD Million)
Table 77. Europe Oncology Biosimilars Revenue by Country (2021-2026) & (USD Million)
Table 78. Europe Oncology Biosimilars Sales by Type (2016-2021e) & (K Units)
Table 79. Europe Oncology Biosimilars Sales by Type (2021-2026) & (K Units)
Table 80. Europe Oncology Biosimilars Sales by Application (2016-2021e) & (K Units)
Table 81. Europe Oncology Biosimilars Sales by Application (2021-2026) & (K Units)
Table 82. Asia-Pacific Oncology Biosimilars Sales by Region (2016-2021e) & (K Units)
Table 83. Asia-Pacific Oncology Biosimilars Sales by Region (2021-2026) & (K Units)
Table 84. Asia-Pacific Oncology Biosimilars Revenue by Region (2016-2021e) & (USD Million)
Table 85. Asia-Pacific Oncology Biosimilars Revenue by Region (2021-2026) & (USD Million)
Table 86. Asia-Pacific Oncology Biosimilars Sales by Type (2016-2021e) & (K Units)
Table 87. Asia-Pacific Oncology Biosimilars Sales by Type (2021-2026) & (K Units)
Table 88. Asia-Pacific Oncology Biosimilars Sales by Application (2016-2021e) & (K Units)
Table 89. Asia-Pacific Oncology Biosimilars Sales by Application (2021-2026) & (K Units)
Table 90. South America Oncology Biosimilars Sales by Country (2016-2021e) & (K Units)
Table 91. South America Oncology Biosimilars Sales by Country (2021-2026) & (K Units)
Table 92. South America Oncology Biosimilars Revenue by Country (2016-2021e) & (USD Million)
Table 93. South America Oncology Biosimilars Revenue by Country (2021-2026) & (USD Million)
Table 94. South America Oncology Biosimilars Sales by Type (2016-2021e) & (K Units)
Table 95. South America Oncology Biosimilars Sales by Type (2021-2026) & (K Units)
Table 96. South America Oncology Biosimilars Sales by Application (2016-2021e) & (K Units)
Table 97. South America Oncology Biosimilars Sales by Application (2021-2026) & (K Units)
Table 98. Middle East & Africa Oncology Biosimilars Sales by Country (2016-2021e) & (K Units)
Table 99. Middle East & Africa Oncology Biosimilars Sales by Country (2021-2026) & (K Units)
Table 100. Middle East & Africa Oncology Biosimilars Revenue by Country (2016-2021e) & (USD Million)
Table 101. Middle East & Africa Oncology Biosimilars Revenue by Country (2021-2026) & (USD Million)
Table 102. Middle East & Africa Oncology Biosimilars Sales by Type (2016-2021e) & (K Units)
Table 103. Middle East & Africa Oncology Biosimilars Sales by Type (2021-2026) & (K Units)
Table 104. Middle East & Africa Oncology Biosimilars Sales by Application (2016-2021e) & (K Units)
Table 105. Middle East & Africa Oncology Biosimilars Sales by Application (2021-2026) & (K Units)
Table 106. Direct Channel Pros & Cons
Table 107. Indirect Channel Pros & Cons
Table 108. Oncology Biosimilars Typical Distributors
Table 109. Oncology Biosimilars Typical Customers
List of Figures
Figure 1. Oncology Biosimilars Picture
Figure 2. Global Oncology Biosimilars Sales Market Share by Type in 2020
Figure 3. Monoclonal Antibody
Figure 4. Hematopoietic Agents
Figure 5. G-CSF
Figure 6. Others
Figure 7. Global Oncology Biosimilars Sales Market Share by Application in 2020
Figure 8. Retail Pharmacies
Figure 9. Hospital Pharmacy
Figure 10. Online Pharmacy
Figure 11. Global Oncology Biosimilars Market Size, (USD Million) & (K Units): 2020 VS 2021 VS 2026
Figure 12. Global Oncology Biosimilars Market Size and Forecast (2016-2026) & (USD Million)
Figure 13. Global Oncology Biosimilars Sales (2016-2026) & (K Units)
Figure 14. Global Oncology Biosimilars Price by Type (2016-2026) & (US$/Unit)
Figure 15. Global Oncology Biosimilars Production Capacity (2016-2026) & (K Units)
Figure 16. Global Oncology Biosimilars Production Capacity by Geographic Region: 2020 VS 2021
Figure 17. Oncology Biosimilars Market Drivers
Figure 18. Oncology Biosimilars Market Restraints
Figure 19. Oncology Biosimilars Market Trends
Figure 20. Global Oncology Biosimilars Sales Market Share by Manufacturer in 2020
Figure 21. Global Oncology Biosimilars Revenue Market Share by Manufacturer in 2020
Figure 22. Oncology Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 23. Top 3 Oncology Biosimilars Manufacturer (Revenue) Market Share in 2020
Figure 24. Top 6 Oncology Biosimilars Manufacturer (Revenue) Market Share in 2020
Figure 25. Global Oncology Biosimilars Sales Market Share by Region (2016-2026)
Figure 26. Global Oncology Biosimilars Revenue Market Share by Region (2016-2026)
Figure 27. North America Oncology Biosimilars Revenue (2016-2026) & (USD Million)
Figure 28. Europe Oncology Biosimilars Revenue (2016-2026) & (USD Million)
Figure 29. Asia-Pacific Oncology Biosimilars Revenue (2016-2026) & (USD Million)
Figure 30. South America Oncology Biosimilars Revenue (2016-2026) & (USD Million)
Figure 31. Middle East & Africa Oncology Biosimilars Revenue (2016-2026) & (USD Million)
Figure 32. Global Oncology Biosimilars Sales Market Share by Type (2016-2026)
Figure 33. Global Oncology Biosimilars Revenue Market Share by Type (2016-2026)
Figure 34. Global Oncology Biosimilars Price by Type (2016-2026) & (US$/Unit)
Figure 35. Global Oncology Biosimilars Sales Market Share by Application (2016-2026)
Figure 36. Global Oncology Biosimilars Revenue Market Share by Application (2016-2026)
Figure 37. Global Oncology Biosimilars Price by Application (2016-2026) & (US$/Unit)
Figure 38. North America Oncology Biosimilars Sales Market Share by Type (2016-2026)
Figure 39. North America Oncology Biosimilars Sales Market Share by Application (2016-2026)
Figure 40. North America Oncology Biosimilars Sales Market Share by Country (2016-2026)
Figure 41. North America Oncology Biosimilars Revenue Market Share by Country (2016-2026)
Figure 42. United States Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Canada Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Mexico Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Europe Oncology Biosimilars Sales Market Share by Type (2016-2026)
Figure 46. Europe Oncology Biosimilars Sales Market Share by Application (2016-2026)
Figure 47. Europe Oncology Biosimilars Sales Market Share by Country (2016-2026)
Figure 48. Europe Oncology Biosimilars Revenue Market Share by Country (2016-2026)
Figure 49. Germany Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. France Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. United Kingdom Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Russia Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Italy Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Asia-Pacific Oncology Biosimilars Sales Market Share by Region (2016-2026)
Figure 55. Asia-Pacific Oncology Biosimilars Sales Market Share by Application (2016-2026)
Figure 56. Asia-Pacific Oncology Biosimilars Sales Market Share by Region (2016-2026)
Figure 57. Asia-Pacific Oncology Biosimilars Revenue Market Share by Region (2016-2026)
Figure 58. China Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Japan Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Korea Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. India Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Southeast Asia Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Australia Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South America Oncology Biosimilars Sales Market Share by Type (2016-2026)
Figure 65. South America Oncology Biosimilars Sales Market Share by Application (2016-2026)
Figure 66. South America Oncology Biosimilars Sales Market Share by Country (2016-2026)
Figure 67. South America Oncology Biosimilars Revenue Market Share by Country (2016-2026)
Figure 68. Brazil Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Argentina Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Middle East & Africa Oncology Biosimilars Sales Market Share by Type (2016-2026)
Figure 71. Middle East & Africa Oncology Biosimilars Sales Market Share by Application (2016-2026)
Figure 72. Middle East & Africa Oncology Biosimilars Sales Market Share by Country (2016-2026)
Figure 73. Middle East & Africa Oncology Biosimilars Revenue Market Share by Country (2016-2026)
Figure 74. Turkey Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Egypt Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Saudi Arabia Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. South Africa Oncology Biosimilars Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
